Organ-on-Chip & Organoids
Emulate
by Emulate, Inc.
Human organ-on-chip technology delivering living tissue models for predictive drug testing
Category
Organ-on-Chip & Organoids
Founded
2013
Headquarters
Boston, MA, USA
Overview
Emulate commercialized the organ-on-chip technology originally developed at Harvard's Wyss Institute, creating microfluidic devices lined with human primary cells or iPSC-derived cells that replicate the mechanical forces, fluid flow, and cellular microenvironment of living organs. Emulate's Organ-Chips — including Intestine-Chip, Liver-Chip, Kidney-Chip, Brain-Chip, and Lung-Chip — allow researchers to test drug absorption, toxicity, and efficacy in physiologically relevant human tissue models outside the body. Major pharmaceutical companies including AstraZeneca, Roche, Janssen, and the FDA's own laboratories use Emulate's technology to screen drug candidates earlier in development, identify mechanisms of off-target toxicity, and reduce reliance on animal models that frequently fail to predict human responses. The FDA has cited Organ-Chip data in regulatory submissions, and the 2022 FDA Modernization Act 2.0 explicitly enabled non-animal alternatives like Organ-Chips as acceptable evidence for drug applications. Emulate's Zoë Culture Module provides the controlled microfluidic environment — precise flow rates, mechanical stretch, and gas concentrations — required to maintain Organ-Chip viability and function for weeks. The company offers a validated platform with application notes, protocols, and analytical assays, enabling pharma scientists to adopt the technology without building internal fluidic expertise. Emulate's multi-organ linking capability allows sequential drug metabolism studies mimicking gut-to-liver first-pass effects.
Key Features
High-Throughput Organoid Screening
Automated platforms test thousands of compounds per experiment on organoid arrays.
Real-Time Tissue Sensing
Embedded sensors capture dynamic tissue responses including TEER, oxygen, and metabolite levels.
Standardized Culture Protocols
Reproducible protocols ensuring consistency across labs and experimental batches.
Disease Modeling
Recreate disease-specific tissue models including fibrosis, inflammation, and tumor microenvironments.
Imaging & Analysis
Integrated confocal imaging and AI-powered image analysis for organoid phenotyping.
Pros & Cons
Pros
- +Multi-organ systems model drug absorption, distribution, metabolism, and excretion in vitro
- +Patient-derived organoids enable personalized drug screening for precision oncology applications
- +Reduces animal testing requirements while improving human-relevant toxicity predictions
- +High-throughput organoid screening platforms test thousands of compounds per experiment
- +Standardized culture protocols ensure reproducibility across labs and experimental batches
- +Real-time sensing and imaging capture dynamic tissue responses to drug exposure
- +Microfluidic organ chips recapitulate human tissue-level physiology for predictive drug testing
Cons
- −Specialized equipment and expertise required for organ chip operation limits broad adoption
- −Organoid variability between batches and labs creates reproducibility challenges
- −Current organ chips cannot fully recapitulate the complexity of whole-organ physiology
- −High per-unit costs for microfluidic chips limit throughput compared to traditional cell culture
Use Cases
Research Workflow Optimization
AI-powered optimization of research workflows to accelerate discovery timelines and improve reproducibility.
Data Analysis & Insights
Machine learning analysis of complex biological datasets to extract actionable insights and identify patterns.
Collaboration & Knowledge Management
Platform-enabled collaboration across distributed research teams with integrated data sharing and knowledge capture.